Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Junho 2023 - 5:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today reported the
grant of 3,250 restricted stock units of Atara’s common stock to
one newly hired employee. This award was approved by the
Compensation Committee of Atara’s Board of Directors and granted
under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a
grant date of June 1, 2023, as an inducement material to the new
employee entering into employment with Atara, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc. Atara Biotherapeutics,
Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging
its novel allogeneic EBV T-cell platform to develop transformative
therapies for patients with serious diseases including solid
tumors, hematologic cancers and autoimmune disease. With our lead
program receiving marketing authorization in Europe, Atara is the
most advanced allogeneic T-cell immunotherapy company and intends
to rapidly deliver off-the-shelf treatments to patients with high
unmet medical need. Our platform leverages the unique biology of
EBV T cells and has the capability to treat a wide range of
EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel for Epstein-Barr virus positive
post-transplant lymphoproliferative disease (EBV+ PTLD) and other
EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV
antigens as a potential treatment for multiple sclerosis; and
multiple next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in Southern California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230602005023/en/
INVESTOR & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024